A rare exception may be P-selectin antagonism in patients undergoing percutaneous coronary intervention for non-ST-segment elevation MI, which blunted post-procedural troponin and creatine kinase-myocardial band rises in blood as surrogates of reduced myocardial damage [53], but clinical endpoints have not been tested in a large follow-up trial. The gene discussed is SELP; the disease is myocardial infarction.